Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics

Immunocore Holdings

Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.

What's Winning in 2022? 3 Stocks That Are Doing Fine

Belite Bio Inc

HilleVax Inc

PepGen Inc

SPDR S&P Biotech ETF

No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerings have sunk to a 10-year low, according to a report from Evaluate.

Biotech Public Offerings at 10-Year Low

Icahn Enterprises

These two dividend stocks have been crushing the bear market this year.

2 Best High-Yield Dividend Stocks to Buy Right Now

British American Tobacco

Donegal Group

It's not easy to be upbeat in a bear market.

3 Red-Hot Dividends In A Down Market

Fate Therapeutics

IVERIC bio Inc

Karuna Therapeutics Inc

Madrigal Pharmaceuticals

Nkarta, Inc.

Seagen

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.

Trial Results Set to Make or Break Small-Cap Pharma Stocks

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO® (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to

Takeda's TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to

Arrowhead Pharmaceuticals

OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)--Results from Phase 2 Study of fazirsiran in patients with alpha-1 antitrypsin deficiency published in New England Journal of Medicine.

Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, today announced that Takeda has leased the entire leading-edge research and development project totaling approximately 600,000 square feet in Kendall Square located at 585 Third Street in Cambridge, Massachusetts. The building is expected to be ready for occupancy in 2026 and will provide 16 stories of advanced and efficient lab office space incorporating

BioMed Realty Announces Landmark Lease with Takeda at 585 Kendall to Accommodate Cambridge Expansion

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories of the future featuring modern design elements and upgraded

Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

Japan's yen is at its weakest in decades and inflicting high costs of imported food and fuel on households and businesses, but also proving to be an unexpected tailwind for multinationals such as pharmaceutical giant Takeda.

Takeda, Nintendo among Japanese firms quietly celebrating weak yen

Gilead Sciences

Takeda's total debt was $35,698.6 million, down 22.1% from the previous year. Takeda Pharmaceutical has a dividend yield of 5.15%, and Gilead Sciences has a dividend yield of 4.53%.

Takeda Pharmaceutical Vs. Gilead Sciences: Who Is The Dividend King?

Costco

Innovative Industrial Properties

Improving your investing process tends to have high returns.

Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years (54 months) after vaccination in the pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. The

Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7 in Chicago, Ill. and the 30th Congress of the European Hematology Association (EHA), June 9-12 in Vienna, Austria. Takeda's latest research in oncology focuses on enhancing and improving patient care w

Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA

Moderna

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda (TSE:4502/NYSE:TAK) announced to transfer the marketing authorization in Japan for Moderna's COVID-19 vaccine Spikevax™ (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022. Moderna will assume responsibility for all Spikevax™ activities, including import, local regulatory, development, quality assurance and com

Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna

Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1, 2022 Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period CAMBRIDGE, MA. and OSAKA, JAPAN / ACCESSWIRE / May 31, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda (TSE:4502)(NYSE:TAK) have announced the transfer of the marketing authorization for Moderna's COVID-19 vaccine SpikevaxTM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022.

Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

Bayer AG

Grifols, S.A.

These three healthcare stocks should hold their value for years.

Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China and emerging markets will be a key driver of growth.

Takeda Pharmaceutical: A Bright Decade Ahead

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2022 Earnings Conference Call May 11, 2022 6:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - CEO Andy Plump - R&D President Constantine Saroukos - CFO Giles Platford - President of the PDT Business Unit Julie Kim - President, U.S. Business Unit & U.S. Country Head Ramona Sequeira - President, Global Portfolio Division Masato Iwasaki - Representative Director Conference Call Participants Shinichiro Muraoka - Morgan Stanley Stephen Barker - Jefferies Seiji Wakao - JPMorgan Chase & Co Stacy Ku - Cowen and Company Fumiyoshi Sakai - Crédit Suisse Hidemaru Yamaguchi - Citigroup Ayako Iwamuro Thank you very much for your participation in Fiscal Year 2021 Earnings webinar of Takeda Pharmaceuticals. I am Ayako Iwamuro, IR of Takeda Pharmaceuticals.

Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q4 2022 Results - Earnings Call Transcript

Takeda Pharmaceutical Co said on Wednesday that 12-month operating profit slid 9.5% from the previous year.

Japan's Takeda Pharma says full-year profit slid 9.5%

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength across its key business areas. Takeda president and chief executive officer, Christophe Weber, commented: “We are pleased to report another year of strong performance, driven by our growth products. I am energized by the impact we are making for patients and by

Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards (FOYA). In the Supply Chain category, Takeda was awarded for its implementation of a new patient-focused supply chain for its allogeneic mesenchymal stem cell therapy; and Takeda's vaccine production facility in Si

Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy Meetings in Salt Lake City, Utah, and the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Lisbon, Portugal between April 23 and 26, 2022. The exploratory data presented at both meetings provide an opportunity to share important new analyses of LIVTENCI

Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older. Novavax licensed and transferred its manufacturing technologies to enable Takeda to develop and manufacture the

Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced TAKHZYRO® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.1 HAE is a rare genetic disease that results in recurrent attacks of edema (swelling) in various parts of the body, which can be burdensome, debilitating and potentially life-threatening.2,3,4 Approved by the U.S. F

Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

News for Takeda Pharmaceutical Stock (TAK)